Kexun Zhou

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Feng Wen, Hanrui Zheng, Pengfei Zhang et al. · Liver International · 2021 · 83 citations

Pharmacy, Oncology, Pharmacoeconomics +15

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer

Kexun Zhou, Jing Zhou, Jiaxing Huang et al. · Lung Cancer · 2019 · 76 citations

Medicine, Oncology, Pharmacoeconomics +16

Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores

Kexun Zhou, Chenlu Jiang, Qiu Li · Lung Cancer · 2019 · 56 citations

Medicine, Oncology, Pharmacology +16

Comprehensive analysis of EMT-related genes and lncRNAs in the prognosis, immunity, and drug treatment of colorectal cancer

Yang Yang, Mingyang Feng, Liangliang Bai et al. · Journal of Translational Medicine · 2021 · 54 citations · Full text

Medicine, Bioinformatics, Oncology +16

A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

Qizhi Ma, Xia He, Benxia Zhang et al. · Signal Transduction and Targeted Therapy · 2022 · 48 citations · Full text

Life Sciences, Immunology, Oncology +17